Newsroom

Sorted by: Latest
-

NATIXIS UK Regulatory Announcement: Form 8.3 Beazley plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

HSBC Bank Plc UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  14-September-2026 Issue: Paragon Bank plc Series 2026-1 XS3432918335 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-July-2026 Date To: 21-September-2026 Record Date: 18-September-2026 Value Date: 21-September-2026 Benchmark Rate: 3.74351% Margin: 0.5% Total Rate: 4.24351% Floor: 0% Number of Days: 68 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Total Amount...
-

Apple’s Outstanding Comedy Widow’s Bay triumphs as the most decorated freshman comedy in Emmy history and Apple TV leads as the most awarded network at the 78th Primetime Emmy Awards

CULVER CITY, Calif.--(BUSINESS WIRE)--This evening at the 78th Primetime Emmy Awards, Apple TV shatters records to become the most awarded network of the year, landing 29 wins overall, including Outstanding Comedy Series for Widow’s Bay as the breakout sensation sweeps all major categories with 14 wins in total and cements itself as the most Emmy-awarded freshman comedy series in history. Additionally, Widow’s Bay lands the most wins for a comedy series in a single season, as well as the most p...
-

Powerful Medical Receives FDA De Novo Approval for PMcardio "Queen of Hearts," Its AI ECG Model for Detecting Acute Heart Attacks

NEW YORK--(BUSINESS WIRE)--Powerful Medical, a leader in AI-driven cardiovascular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for Queen of Hearts (ACS AI ECG Model). The AI-powered model is designed to identify ECG findings suggestive of urgent acute coronary syndrome (ACS), which can include ST-segment elevation myocardial infarction (STEMI) and STEMI equivalents, and urgently notify clinicians of suspected cases. Heart attack...
-

UK Debt Management Office UK Regulatory Announcement: Issue of Debt

LONDON--(BUSINESS WIRE)--    DMO-TAS041/3728/002         The Minster Building21 Mincing LaneLondonEC3R 7AG T 020 7862 6500F 020 7862 6509www.dmo.gov.uk           A122\26 15 September 2026   PRESS NOTICE   RESULT OF THE SALE BY TENDER OF UP TO £1250 MILLION OF 0½% TREASURY GILT 2029The United Kingdom Debt Management Office ("DMO") announces that the tender of up to £1,250 million of 0½% Treasury Gilt 2029 (ISIN Code: GB00BLPK7227) has been allocated as follows:(Note: all prices in this notice ar...
-

ChatGPT Ads startet in Europa – Adform ist Technologieplattformpartner

HAMBURG, Deutschland--(BUSINESS WIRE)--Marken und Agenturen buchen ChatGPT Ads ab sofort über Adform und messen sie gemeinsam mit ihren übrigen Kampagnen...
-

Genexine’s GX-BP1 (SOX2 bioPROTAC) Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination

SEOUL, South Korea--(BUSINESS WIRE)--Genexine, Inc. (KOSDAQ: 095700) announced that Jaehyun Choi, Ph.D., CEO and Head of R&D, presented new preclinical data for GX-BP1, the company’s SOX2-targeting bioPROTAC, at the 2026 World Conference on Lung Cancer (WCLC) in Seoul on September 13. The mini oral presentation, titled ‘Lung-Targeted mRNA-LNP Delivery of SOX2 bioPROTAC: A Comprehensive Strategy for LUAD, LUSC, and SCLC in Monotherapy and Combination Settings’ highlighted the potential of GX...
-

Samenvatting: Axo Longevity haalt een overtekende startkapitaalronde van $5M op om Europa’s toonaangevend lidmaatschap voor preventieve gezondheidszorg uit te bouwen

LONDEN & MADRID--(BUSINESS WIRE)--Axo Longevity kondigde vandaag de afsluiting aan van een overtekende startkapitaalronde van $5M om zijn lidmaatschap voor preventieve gezondheidszorg in heel Europa uit te breiden. De ronde werd gesteund door MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital en NIAN Sports & Entertainment, samen met angel-investeerders waaronder Dr. Jorge Planas van Clinica Planas Barcelona en Daniel Kulle, voormalig v...
-

Axo Longevity lève 5 millions de dollars lors d’un cycle d’amorçage sursouscrit pour développer le premier programme d’adhésion en matière de santé préventive en Europe

LONDRES et MADRID--(BUSINESS WIRE)--Axo Longevity a annoncé aujourd’hui la clôture d’un cycle d’amorçage sursouscrit de 5 millions de dollars destiné à développer son programme d’adhésion en matière de santé préventive à travers l’Europe. Ce tour de table a été soutenu par MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital et NIAN Sports & Entertainment, ainsi que par des investisseurs providentiels, notamment le Dr Jorge Planas de la C...
-

Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership

LONDON & MADRID--(BUSINESS WIRE)--Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership...